[18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco‐ablative therapies for hepatocellular carcinoma

Yael Asman, Amy R. Evenson, Einat Even‐Sapir, Oren Shibolet – 31 January 2015 – Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer‐related death worldwide. Orthotopic liver transplantation (OLT) and resection are curative treatment options for well‐selected patients with HCC, whereas loco‐ablative therapy has been shown to prolong survival.

Impact of elderly donors for liver transplantation: A single‐center experience

Naoko Kamo, Toshimi Kaido, Ahmed Hammad, Kohei Ogawa, Yasuhiro Fujimoto, Tadahiro Uemura, Akira Mori, Etsuro Hatano, Hideaki Okajima, Shinji Uemoto – 31 January 2015 – Elderly donor grafts for liver transplantation (LT) are recognized to be marginal grafts. The present study investigated the impact of using elderly donors for LT. Between June 1990 and August 2012, 1631 patients received LT at Kyoto University Hospital. Out of 1631 patients, 1597 patients received living donor liver transplantation (LDLT), whereas the other 34 patients underwent deceased donor liver transplantation (DDLT).

Tenofovir‐associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection

Hyeon Seok Hwang, Cheol Whee Park, Myeong Jun Song – 30 January 2015 – Tenofovir disoproxil fumarate (TDF) is widely used as an effective first‐line therapy for chronic hepatitis B (CHB) infection. While TDF demonstrates successful viral suppression, it has been linked to the development of renal proximal tubular (PT) dysfunction, leading to Fanconi syndrome. However, Fanconi syndrome has been rarely reported in CHB‐monoinfected patients, and there were no reports of TDF‐associated nephrotic syndrome.

Tenofovir‐associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection

Hyeon Seok Hwang, Cheol Whee Park, Myeong Jun Song – 30 January 2015 – Tenofovir disoproxil fumarate (TDF) is widely used as an effective first‐line therapy for chronic hepatitis B (CHB) infection. While TDF demonstrates successful viral suppression, it has been linked to the development of renal proximal tubular (PT) dysfunction, leading to Fanconi syndrome. However, Fanconi syndrome has been rarely reported in CHB‐monoinfected patients, and there were no reports of TDF‐associated nephrotic syndrome.

Tumor‐infiltrating, interleukin‐33–producing effector‐memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival

Stefan M. Brunner, Christoph Rubner, Rebecca Kesselring, Maria Martin, Eva Griesshammer, Petra Ruemmele, Thomas Stempfl, Andreas Teufel, Hans J. Schlitt, Stefan Fichtner‐Feigl – 30 January 2015 – Interleukin‐33 (IL‐33), a cytokine with pleiotropic functions, is elevated in serum of patients with hepatocellular carcinoma (HCC). This study investigated the effects of local IL‐33 expression in resected HCC on patient survival and on the immunological and molecular tumor microenvironment.

Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography–defined subclinical cirrhosis

Mi Na Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Ki Jun Song, Young Nyun Park, Kwang‐Hyub Han – 30 January 2015 – Early detection of liver cirrhosis in its subclinical stage is of paramount importance to identify high‐risk individuals for developing hepatocellular carcinoma (HCC). This study investigated whether transient elastography (TE) can identify patients with subclinical cirrhosis (SCC) who are at increased risk of developing HCC among chronic hepatitis B (CHB) patients without clinical evidence of cirrhosis.

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014

Natalie J. Torok, Jonathan A. Dranoff, Detlef Schuppan, Scott L. Friedman – 27 January 2015 – There is an urgent need to develop antifibrotic therapies for chronic liver disease, and clarify which endpoints in antifibrotic trials will be acceptable to regulatory agencies. The American Association for the Study of Liver Diseases sponsored an endpoints conference to help accelerate the efficient testing of antifibrotic agents and develop recommendations on clinical trial design for liver fibrosis.

Interaction of tetraspan(in) TM4SF5 with CD44 promotes self‐renewal and circulating capacities of hepatocarcinoma cells

Doohyung Lee, Juri Na, Jihye Ryu, Hye‐Jin Kim, Seo Hee Nam, Minkyung Kang, Jae Woo Jung, Mi‐Sook Lee, Haeng Eun Song, Jungeun Choi, Gyu‐Ho Lee, Tai Young Kim, June‐Key Chung, Ki Hun Park, Sung‐Hak Kim, Hyunggee Kim, Howon Seo, Pilhan Kim, Hyewon Youn, Jung Weon Lee – 27 January 2015 – Tumor metastasis involves circulating and tumor‐initiating capacities of metastatic cancer cells. Epithelial‐mesenchymal transition (EMT) is related to self‐renewal capacity and circulating tumor cell (CTC) characteristics for tumor metastasis.

Subscribe to